Sign in

Emily Chudy

Research Analyst at Stifel Financial Corp.

Emily Chudy is an Associate specializing in Biotechnology Equity Research at Stifel Financial Corp., where she contributes thorough analysis and industry insights covering companies such as Alector, Inc. Her research supports Stifel's biotechnology sector offerings, and her performance is reflected in precise, data-driven analysis relevant to key public earnings events. Emily began her equity research career at Stifel and is presently registered as a securities broker, holding FINRA Series 7 and Series 63 licenses. She is recognized for her analytical depth and emerging track record within life sciences investment research.

Emily Chudy's questions to Xenon Pharmaceuticals (XENE) leadership

Emily Chudy's questions to Xenon Pharmaceuticals (XENE) leadership • Q2 2025

Question

Emily Chudy of Stifel Financial Corp. inquired about the anticipated timeline for an NDA filing following the top-line data for focal onset seizures (FOS) and sought reassurance on how Xenon would avoid safety issues with its Nav1.7 pain program, which have affected similar mechanisms in the past.

Answer

President and CEO Ian Mortimer stated that an NDA filing is expected approximately six months after the top-line data readout. Regarding the Nav1.7 program, he expressed confidence that Xenon has addressed potential cardiovascular risks seen in earlier drugs through its molecule's specific profile and noted the absence of any such signals in preclinical safety data.

Ask Fintool Equity Research AI